Susan E. Kephart
Publications by Year
Research Areas
Cancer-related gene regulation, Cancer-related Molecular Pathways, Crystallization and Solubility Studies, Synthesis and Catalytic Reactions, X-ray Diffraction in Crystallography
Most-Cited Works
- → Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth(2010)320 cited
- → Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor(2021)172 cited
- → Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)(2017)126 cited
- → Silicon-directed aldol reactions. Rate acceleration by small rings(1992)114 cited
- → Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer(2021)112 cited
- → Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants(2016)93 cited
- → Systematic Structure Modifications of Imidazo[1,2-a]pyrimidine to Reduce Metabolism Mediated by Aldehyde Oxidase (AO)(2011)80 cited
- → Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2 H )-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors(2016)68 cited
- → Discovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor Antagonists(2011)67 cited
- → Discovery of Pyrroloaminopyrazoles as Novel PAK Inhibitors(2012)60 cited